- Home
- MKL vs GH Comparison
MKL vs GH Comparison
Compare MKL & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKL | GH |
|---|---|---|
| Founded | 1930 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2B | 22.9B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MKL | GH |
|---|---|---|
| Price | $1,972.32 | $152.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 26 |
| Target Price | ★ $1,980.17 | $200.76 |
| AVG Volume (30 Days) | 61.7K | ★ 2.2M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 91.90 | N/A |
| Revenue | ★ $15,513,233,000.00 | $982,021,000.00 |
| Revenue This Year | N/A | $39.14 |
| Revenue Next Year | N/A | $35.11 |
| P/E Ratio | $21.37 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $1,704.17 | $74.55 |
| 52 Week High | $2,207.59 | $191.05 |
Technical Indicators
Market Signals| Indicator | MKL | GH |
|---|---|---|
| Relative Strength Index (RSI) | 70.47 | 39.49 |
| Support Level | $1,918.84 | $138.64 |
| Resistance Level | $2,008.51 | $177.55 |
| Average True Range (ATR) | 34.58 | 10.13 |
| MACD | 4.82 | -1.95 |
| Stochastic Oscillator | 84.33 | 33.14 |
Price Performance
Historical ComparisonAbout MKL Markel Group Inc.
Markel's primary business is property-casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.